Takotsubo cardiomyopathy (TCM), colloquially known as “broken heart syndrome,” is a relatively uncommon transient condition that is characterized by left ventricular apical ballooning [1]. It is purported to be triggered by exorbitant physical or emotional stressors. The clinical picture elicited by TCM closely mimics that of acute coronary syndrome (ACS), with most patients presenting with substernal chest pain and ECG changes akin to those observed in a patient with acute myocardial infarction [1]. Interestingly, in cases of TCM, coronary arteries are noted to be unremarkable upon catheterization [1,2]. Due to the remarkably similar clinical semblance elicited by TCM and myocardial infarction, it remains critically imperative to distinguish between the two pathologies. Of note, TCM remains a diagnosis of exclusion, and ischemic cardiomyopathy must be excluded prior to its diagnosis. The diagnosis of TCM is rendered in accordance with the criteria outlined by Mayo Clinic [3]. This is delineated by Fig. 1.

A systematic review by Gianni et al. divulged that chest pain and dyspnea were the most commonly reported features of TCM [2]. Chest pain was noted to be the chief presenting complaint in 185 of 273 patients (67.8%, 95% CI: 62.0–73.0%; range: 20–94.7%) while dyspnea was noted in merely 40 of 225 patients (17.8%, 95% CI: 13.3–23.3%; range: 4.5–55.5%) who were diagnosed with the ailment. Gianni et al. also established a causal link between TCM and preceding emotional or physical stressors. A prior history of emotional stressors, such as the death of loved ones and insurmountable financial losses, was noted in merely 40 of 225 patients (17.8%, 95% CI: 13.3–23.3%; range: 4.5–55.5%) who were diagnosed with the ailment. Gianni et al. always be a sequel of stress [2]. While the medical literature remains largely bereft of studies elucidating a causal relationship between underlying viral infections and TCM, reports surrounding coronavirus disease 2019 (COVID-19) induced TCM have started to surface [4–10]. A brief consideration of the pathophysiology underlying COVID-19 induced takotsubo cardiomyopathy is therefore warranted.

One widely proposed mechanism of COVID-19 induced cardiac injury is directly through the angiotensin converting enzyme 2 (ACE2) receptor, a receptor ubiquitous in the myocardium [4]. The destruction of ACE2 receptors is believed to lead to cardiac injury (1) directly by reducing ACE-2 activity, thereby thwarting the conversion of angiotensin I and II to cardioprotective peptides and (2) indirectly through systemic inflammation and fibrosis [5,6]. Although the underlying pathophysiology of TCM remains at the epicenter of a cardiology conundrum, the transient myocardial changes observed are generally attributed to a surge in catecholamines, such as epinephrine, that is triggered by preceding physical or emotional stress. Furthermore, the observed myocardial changes—the most common of which being apical ballooning of the left ventricle—are transient. Nevertheless, these propositions fail to encompass the mechanisms that underlie COVID-19 induced TCM.

The acute viral illness, severe hypoxia, and the associated acute respiratory distress syndrome (ARDS), as observed in moderate-to-severe COVID-19 infections, can trigger an indirect surge in catecholamines through their sympathetic effects via the adrenergic β1 receptors ubiquitous in the myocardium, culminating in an overactive myocardium [7]. Additionally, modulations in catecholamine sensitivity of the myocardium, mediated by a cytokine storm, are suspected to be critical in the biological and physical manifestations of the disease.

Cytokine storm in the aftermath of a severe SARS-CoV-2 infection has been reported extensively in the literature, with higher levels
associated with increased disease severity [4,6–8]. One hypothesis, therefore, would propose two major deleterious effects of the cytokine storm: (1) acting as a physical and chemical stressor in and of themselves as well as (2) increasing catecholamine levels concurrent with an increased hypersensitivity to these catecholamines [11]. Further substantiating this notion is the evidence that elevated levels of catecholamines were discovered to be released locally at the aortic root and the coronary sinus in patients with TCM secondary to COVID-19 [7]. Additionally, patients who have underlying cardiac comorbidities boast higher baseline levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and related proinflammatory cytokines, further heralding the onset of TCM [9,11]. Furthermore, COVID-19 can present with a cytokine storm syndrome, which was shown to be associated with a catecholamine surge that may exacerbate pre-existing TCM [9,12,13]. Sufficient alterations to \( \beta_2 \) receptors in a segment of the myocardium can lead to akinesis and stunning. Alterations in \( \beta_1 \) were also evidenced by biopsy samples performed in vivo: patients with TCM were shown to have higher levels of a G-protein coupled receptor kinase 2 (GRK2) and \( \beta \)-arrestin2 than patients with dilated cardiomyopathy. As GRK2 and \( \beta \)-arrestin2 are known to desensitize the \( \beta \)-adrenergic receptor and \( \beta_1 \) and \( \beta_2 \) receptors are found together in an apical distribution within the heart, the aforesaid observations could explain the apical ballooning that is seen most frequently in TCM [7].

TCM has also been described in other viral infections. Myocardial involvement has been reported in up to ten percent of influenza cases, with a preponderance of myocarditis cases of varying degrees [14]. One particular case described a 57-year-old woman with an influenza infection and ostensible viral myocarditis [14]. However, given her past history of TCM, the typical TCM ventricular morphology observed through angiogram and echocardiogram, and the restoration of ventricular function, TCM was deemed more plausible. These mechanisms epinephrine was shown to elicit a cardioprotective response on the myocardium, resulting in a change in the \( \beta_2 \) receptor response to that of a G\(_1\)-protein, the consequences of which are negative inotropy [7].

Myocardial stunning due to left ventricular hypokinesis, dyskinesis, or akinesis, which results in a reduced left ventricular ejection fraction, is another proposed mechanism underlying COVID-19 induced TCM [10]. This would support the fact that patients typically present with symptoms akin to those fomented by ACS but without evidence of coronary artery disease or myocyte damage. In one rat model, high dose

Fig. 1. A pictorial depiction of the Mayo Clinic criteria for the diagnosis of takotsubo cardiomyopathy [3].
could also portend implications in cases of COVID-19 induced TCM.

In a review of 7 case reports documenting TCM associated with SARS-CoV-2, most patients presented with ECG changes such as ST-segment elevation or T-wave inversion \([8,15–17]\). Elevated troponin levels were noted in the majority of cases along with reduced left ventricular ejection fraction (LVEF) \([4,8,16–19]\). Additionally, the echocardiogram divulged underlying apical ballooning, insinuating a diagnosis of TCM. Once identified and managed, most patients showed rapid amelioration in their LVEF, further supporting the diagnosis of SARS-CoV-2-induced TCM. These findings are elucidated by Table 1 below.

Lastly, a final proposed stressor that may be overlooked is the emotional and psychological toll caused by the COVID-19 pandemic. In one retrospective study of 1914 patients that presented with acute coronary syndrome during the pandemic, the incidence of stress cardiomyopathy was 7.8% compared to the baseline pre-pandemic incidence of 1.5–1.8%, an incidence ratio of 4.58 (95% CI: 4.11–5.11, \( p < 0.001 \)) \([20]\). Notably, all the patients in the study tested negative for SARS-CoV-2 in a reverse transcriptase polymerase chain reaction (RT-PCR) test. As the COVID-19 pandemic continues to wreak havoc, its noxious effects on the emotional and mental health cannot be discounted. While these parameters are more subjective and may not be as easily quantifiable, it is clear that the difficulties inherent in social isolation and “the new normal” are undeniably detrimental to mental health, further increasing the likelihood of developing TCM.

**Ethical approval**

NA.

**Funding**

NA.

**Author contribution**

TA, TK, AH: conceived the idea, designed the study, and drafted the manuscript.

RA, LA, AHA: conducted literature search and created the illustrations.

RA, AHA: revised the manuscript critically and refined the illustrations.

MSP, HUHV: revised the final version of the manuscript critically and gave the final approval.

**Consent**

NA.

**Registration of research studies**

1. Name of the registry: NA.
2. Unique Identifying number or registration ID: NA.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): NA.

**Guarantor**

Talal Almas
RCSI University of Medicine and Health Sciences
123 St. Stephen’s Green
Dublin 2, Ireland
Talalalmas.almas@gmail.com
+353834212442

**Declaration of competing interest**

None.

**References**

[1] Z.R. Brenner, J. Powers, Takotsubo cardiomyopathy, Heart Lung 37 (1) (2008) 1–7, https://doi.org/10.1016/j.hl.2006.12.003. PMID: 18206521.

[2] M. Gianni, F. Dentali, A.M. Grandi, G. Sumner, R. Hiralal, E. Lonn, Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review, Eur. Heart J. 27 (13) (2006) 1523–1529, https://doi.org/10.1093/eurheartj/ehl032. PMID: 16720686.

[3] M. Madhavan, A. Prasad, Proposed Mayo Clinic criteria for the diagnosis of Takotsubo cardiomyopathy, JACC Cardiovascular Imaging 1 (11) (2008) 1234–1242, https://doi.org/10.1016/j.jcmg.2008.09.001. PMID: 19019896.

[4] J.M.D. Gomez, G. Nair, P. Nanavaty, A. Rao, K. Marinescu, T. Suboc, COVID-19-associated takotsubo cardiomyopathy, BMJ Case Rep. 13 (12) (2020), e236811, https://doi.org/10.1136/bcr-2020-236811.

[5] A. Tushchyan, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cardiovascular syndrome: etiology, outcomes, and management, Cureus 12 (6) (2020), e236561, https://doi.org/10.1136/bcr-2020-236561. PMID: 32724831.

[6] H. Okura, Update of takotsubo syndrome in the era of COVID-19, J. Cardio. 77 (4) (2021) 361–369, https://doi.org/10.1136/jjcc.2020.369.

[7] F. Taza, M. Zulty, A. Kanwal, D. Grove, Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patient, BMJ Case Rep. 13 (6) (2020), e236561, https://doi.org/10.1136/bcr-2020-236561.
[9] S. Singh, R. Desai, Z. Gandhi, et al., Takotsubo syndrome in patients with COVID-19: a systematic review of published cases, SN Compr. Clin. Med. 2 (2020) 2102–2108, https://doi.org/10.1007/s42399-020-00557-w.

[10] L. Oyarzabal, J.A. Gómez-Hospital, J. Comín-Colet, Tako-tsubo syndrome associated with COVID-19, Rev. Esp. Cardiol. 73 (10) (2020) 846, https://doi.org/10.1016/j.rec.2020.06.021.

[11] K. Esposito, F. Nappo, R. Marfella, et al., Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress, Circulation 106 (16) (2002) 2067–2072, https://doi.org/10.1161/01.cir.0000034509.14906.x.

[12] V. Staedtke, R.Y. Bai, K. Kim, et al., Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome, Nature 564 (7735) (2018) 273–277, https://doi.org/10.1038/s41586-018-0774-y.

[13] P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, HLH across Speciality Collaboration, UK: COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet 395 (10229) (2020) 1033–1034, https://doi.org/10.1016/S0140-6736(20)30628-0.

[14] J. Buzon, O. Roignot, S. Lemoine, et al., Takotsubo cardiomyopathy triggered by influenza A virus, Intern. Med. 54 (2015) 2017–2019, https://doi.org/10.2169/internalmedicine.54.3606.

[15] P. Meyer, S. Degrauwe, C. Van Delden, J.R. Ghadri, C. Templin, Typical takotsubo syndrome triggered by SARS-CoV-2 infection, Eur. Heart J. 41 (19) (2020) 1860, https://doi.org/10.1093/eurheartj/ehaa306.

[16] E. Roca, C. Lombardi, M. Campana, et al., Takotsubo syndrome associated with COVID-19, Eur. J. Case Rep. Intern. Med. 7 (5) (2020), 001665, https://doi.org/10.12890/2020.001665.

[17] van Osch D, Ansebergs FW, Teske AJ: Takotsubo cardiomyopathy in COVID-19: a case report. Haemodynamic and therapeutic considerations. Eur. Heart J.: Case Rep. 10.1093/ehjcr/ytaa271.

[18] Y. Sattar, M. Connorney, W. Ullah, et al., COVID-19 Presenting as takotsubo cardiomyopathy complicated with atrial fibrillation, Int. J. Cardiol. Heart Vasculatione 29 (2020) 100580, https://doi.org/10.1016/j.ijcha.2020.100580.

[19] A.S. Minhas, P. Scheel, B. Garibaldi, et al., Takotsubo syndrome in the setting of COVID-19, JACC Case Rep. 2 (9) (2020) 1321–1325, https://doi.org/10.1016/j.jaccas.2020.04.023.

[20] A. Jabri, A. Kalra, A. Kumar, et al., Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic, JAMA Netw. Open 3 (7) (2020), e2014780, https://doi.org/10.1001/jamanetworkopen.2020.14780.